Thank you for pointing that out. I based my figure on a study (link below) published in JAMA. While I’m not familiar with how anaphylaxis is diagnosed, I think anaphylaxis reactions reported to VAERS do not necessarily mean actual anaphylaxis diagnoses. The JAMA study appears to use the “Brighton Collaboration case definition for anaphylaxis to classify cases.”

https://jamanetwork.com/journals/jama/fullarticle/2776557

Or it could be that anaphylaxis is less common in the vulnerable populations that were prioritized during the early vaccination rollout, leading to increasing rates as the less vulnerable populations are getting vaccinated. Or it could be a combination of both.